Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes
2015
Abstract Maraviroc is approved for treatment-experienced HIV+ adults in twice-daily administration. Limited data are available on safety, efficacy and use in routine clinical practice, outside of restrictive clinical trials. This retrospective multicenter (27 centers) study included 667 subjects starting a regimen with maraviroc. The primary endpoint was plasma HIV-RNA + cell count change at 48 and 96 weeks (FDA snapshot analysis). 94.4% had CCR5 tropism (58.3% Trofile™, 29.2% population genotype, and 12% genotyping proviral DNA). Half of the subjects received the drug in scenarios or dosages outside the initial approval. Maraviroc was prescribed for salvage in 346 (51.9%) individuals, as a switch strategy due to toxicity in 135 (38.7%), for immune discordance in 75 (11.2%), and for simplification in 48 (7.2%). After salvage therapy, 223 (64.5%) subjects had HIV-RNA p + counts was seen at 48 and 96 weeks in subjects with immune discordance ( p
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
36
References
12
Citations
NaN
KQI